FOXO4-DRI Dosage, half-life & reference guide
Also known as FOXO4-p53 DRI peptide · Senostatic peptide
An experimental senolytic peptide: in mice it selectively triggers the death of "zombie cells" (senescent cells) that build up with age and release inflammatory signals, by disrupting the survival switch they rely on.
- Studied range
- 1–2 mg
- How often
- 3× weekly
- Half-life
- Hours
- Evidence
- ●
●●Emerging - Route
- SubQ injection
Studied in research — not a recommendation.
How it works.
D-retro-inverso peptide that disrupts the FOXO4–p53 interaction in senescent cells, triggering apoptosis of senescent cells specifically. Experimental senolytic for clearing senescent cell burden.
Commonly reported: Fatigue and flu-like malaise on dosing days, and for some better skin or less joint stiffness in the weeks after a run. It has only been studied in mice and cells, with no human safety data, and is used in short, infrequent cycles.
Where FOXO4-DRI works.
Energy & longevity
In animals. D-retro-inverso peptide that disrupts the FOXO4–p53 interaction in senescent cells, triggering apoptosis of senescent cells specifically.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
Day 1–7Animal
The hit-and-run protocol
FOXO4-DRI is used as a pulse, not a chronic dose — 3x/week for about two weeks, then nothing for months. Commonly reported: mild fatigue, a flu-like feeling or brief weakness in the first few days. Why isn't known, and there are no human safety data, so strong or lasting symptoms are a reason to stop and talk to a clinician.
The science
The peptide disrupts the FOXO4–p53 interaction that senescent cells use to evade apoptosis. Once disrupted, p53 is released and drives selective apoptosis of senescent cells (not healthy ones) in cell and mouse studies. Baar et al. 2017 showed this in fast-aging and naturally aged mice, with better fitness, fur density and kidney function.
Sources- Baar et al. (2017)
Updated Sep 2026
Day 7–21Animal
Post-clearance recovery
The active dosing window is typically 2 weeks, then you stop and let the body recover. Some users report noticeable improvements in skin quality, joint stiffness, and general "clearance" feel 2–4 weeks after stopping — the effect shows up after, not during.
The science
In aged mice, selective senescent cell clearance produced phenotype improvements — hair density, physical activity, kidney function — measured weeks after dosing ended. This is why FOXO4-DRI is used infrequently (1–2x/year at most) — it's a pulse-and-wait compound, not a daily protocol.
Sources- Baar et al. (2017)
Updated Apr 2026
Day 21–60Community
Hold off before the next round
Done with the cycle? Don't rush back. Senescent cell burden doesn't rebuild in weeks — the next sensible dosing window is 6–12 months out. Aggressive repeat protocols aren't supported by any data.
The science
Senescent cell accumulation is a slow process measured across years. Repeat intervals are community convention: the mouse studies dosed in short series and didn't test repeat cycles months apart. No human pharmacokinetic or safety data exists for repeat FOXO4-DRI cycles.
Sources- Baar et al. (2017)
Updated Sep 2026
Any dayAnimal
What FOXO4-DRI is built on
This is an experimental senolytic with a single landmark animal paper and zero human trials. The mechanism is interesting and community reports exist, but the evidence base is young. Approach as early-stage self-experimentation, not established protocol.
The science
Baar et al. 2017 (Cell) is the foundational paper — D-retro-inverso peptide, selective senescent cell apoptosis via FOXO4-p53 disruption, reversed aging phenotypes in mice. No human safety studies, no pharmacokinetics in humans, no established dosing protocol beyond extrapolation from the rodent paper. In mouse models of pulmonary hypertension, eliminating senescent cells, including with FOXO4-DRI, worsened pulmonary hemodynamics (Born 2023), the only published harm signal so far.
Sources- Baar et al. (2017)
- Born et al. (2023)
Updated Sep 2026
Day 1 is the day you start it.
Mixing and a typical run.
Example numbers
Reconstitution example
Reconstitute a 10 mg vial of FOXO4-DRI with 2 mL of bacteriostatic water and a 2 mg dose is 40 units on a U-100 syringe, about 5 doses per vial.
- Vial
- 10 mg
- Water
- 2 mL
- Amount
- 2 mg
Draw to40 units
0.5 mL insulin syringe · 50 units
Run notes
- Cycle
- Very short cycles only — 3x/week for 1–2 weeks, infrequently (1–2x per year). Experimental compound. In mouse research it's studied beside navitoclax (ABT-263), another senolytic, which isn't in this library.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Typically morning injection. Strict cycle limits due to senolytic mechanism.
- Route
- SubQ injection
- Stacks
- MOTS-c
Safety.
Common side effects
- Fatigue
- Flu-like symptoms
- Transient weakness
- Hair thinning (reported)
Goes with.
Questions people ask.
What is FOXO4-DRI?
An experimental senolytic peptide: in mice it selectively triggers the death of "zombie cells" (senescent cells) that build up with age and release inflammatory signals, by disrupting the survival switch they rely on.
How is FOXO4-DRI dosed in research?
The research range for FOXO4-DRI is 1–2 mg, 3x/week (short cycles). Studied in research — not a recommendation.
How long does FOXO4-DRI last?
The half-life of FOXO4-DRI is hours.
What do people report on FOXO4-DRI?
Commonly reported on FOXO4-DRI: fatigue and flu-like malaise on dosing days, and for some better skin or less joint stiffness in the weeks after a run. It has only been studied in mice and cells, with no human safety data, and is used in short, infrequent cycles.
Is FOXO4-DRI safe?
The research basis for FOXO4-DRI is emerging: primarily preclinical / limited human data. Common side effects in the library: fatigue, flu-like symptoms, transient weakness and hair thinning (reported).
What does FOXO4-DRI stack with?
Common stacks for FOXO4-DRI: MOTS-c.
Research.
Reference.
- Cadence
3× weekly
3x/week (short cycles)
- Half-life
Hours
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
PepVault for iPhone
Track FOXO4-DRI in PepVault
Log every dose and keep your vial and the doses left in it. 7 days free on the yearly plan for new subscribers.
Open the calculatorHow the vial count worksExplore the live demo
Reviewed How we check the library